Study of therapeutic potential of the experimental pseudomonas bacteriophage preparation
- PMID: 17660609
Study of therapeutic potential of the experimental pseudomonas bacteriophage preparation
Abstract
Wide expansion of the infections caused by multi-antibiotic resistant strains of P. aeruginosa revived the idea of phage therapy with pseudomonas phage preparations for treatment and prevention of the bacterial infection diseases. The purpose of this study was examination of an experimental series of the therapeutic-prophylactic pseudomonas bacteriophage preparation, with wide spectra of lytical activity and high therapeutic potential. Newly isolated phage clones of P. aeruginosa were studied by the basic tests (such as host range, lysis stability, physiological and immunogenic properties of the phages, host dependent restriction/modification phenomena and automatic reproduction ability of the phages on the UV inactivated strains) determining their virulent nature. An experimental series of the therapeutic-prophylactic pseudomonas phage preparation were developed from the genuine virulent phage clones CF1/1; CF1/7; P.a.N1, P.a.N2 and P.a.N4. The phage preparation successfully passed in vitro (efficacy, sterility, stability) and in vivo (safety, definition of therapeutic potential) controls on experimental animals (white mice). The host range of the experimental pseudomonas phage preparation equals 99.5% of 206 strains of P. aeruginosa. Preclinical testing of the experimental pseudomonas phage preparation on white mice revealed that the therapeutic efficacy of the phage preparation was higher (80-100%) than that of the antibiotic-ciprinol (50-80%). Noteworthy, 100% therapeutic efficacy was observed after combined application of the antibiotic and the phage preparation.
Similar articles
-
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.Clin Otolaryngol. 2009 Aug;34(4):349-57. doi: 10.1111/j.1749-4486.2009.01973.x. Clin Otolaryngol. 2009. PMID: 19673983 Clinical Trial.
-
Use of newly isolated phages for control of Pseudomonas aeruginosa PAO1 and ATCC 10145 biofilms.Res Microbiol. 2011 Oct;162(8):798-806. doi: 10.1016/j.resmic.2011.06.010. Epub 2011 Jul 5. Res Microbiol. 2011. PMID: 21782936
-
Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections.J Infect Dis. 2010 Apr 1;201(7):1096-104. doi: 10.1086/651135. J Infect Dis. 2010. PMID: 20196657
-
Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy.Adv Virus Res. 2014;88:227-78. doi: 10.1016/B978-0-12-800098-4.00005-2. Adv Virus Res. 2014. PMID: 24373314 Review.
-
Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections.J Virol. 2015 Aug;89(15):7449-56. doi: 10.1128/JVI.00385-15. Epub 2015 May 13. J Virol. 2015. PMID: 25972556 Free PMC article. Review.
Cited by
-
Phage vB_PaeS-PAJD-1 Rescues Murine Mastitis Infected With Multidrug-Resistant Pseudomonas aeruginosa.Front Cell Infect Microbiol. 2021 Jun 11;11:689770. doi: 10.3389/fcimb.2021.689770. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34178726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources